NASDAQ: GENBGenerate Biomedicines Inc Stock Ownership - Who owns Generate Biomedicines?
Insider buying vs selling
Have Generate Biomedicines Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Noubar Afeyan | Director | 2026-03-02 | 1,562,500 | $16.00 | $25.00MBuy |
| Beth Grous | Chief People Officer | 2026-03-02 | 300 | $16.00 | $4.80kBuy |
| Jane L. Mendillo | Director | 2026-03-02 | 1,500 | $16.00 | $24.00kBuy |
| Jason Silvers | President CFO | 2026-03-02 | 500 | $16.00 | $8.00kBuy |
| Jason Silvers | President CFO | 2026-03-02 | 500 | $16.00 | $8.00kBuy |
GENB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GENB insiders and whales buy or sell their stock.
GENB Shareholders
What type of owners hold Generate Biomedicines Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Noubar Afeyan | 49.17% | 62,673,117 | $772.76M | Insider |
| Michael Nally | 2.25% | 2,869,154 | $35.38M | Insider |
| Stephane Bancel | 0.93% | 1,184,989 | $14.61M | Insider |
| Gevorg Grigoryan | 0.52% | 659,973 | $8.14M | Insider |
| Frances Arnold | 0.36% | 464,944 | $5.73M | Insider |
| Jane L. Mendillo | 0.00% | 1,500 | $18.50k | Insider |
| Jason Silvers | 0.00% | 1,500 | $18.50k | Insider |
| Beth Grous | 0.00% | 300 | $3.70k | Insider |
Generate Biomedicines Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.